{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:38:49Z","timestamp":1782977929635,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.cct.2023.107198","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T11:02:27Z","timestamp":1681556547000},"page":"107198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The effect of the COVID-19 pandemic on US Food and Drug Administration-funded clinical trials and natural history studies for rare diseases"],"prefix":"10.1016","volume":"129","author":[{"given":"Kathleen L.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine I.","family":"Miller Needleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cct.2023.107198_bb0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jval.2018.03.004","article-title":"Challenges in research and health technology assessment of rare disease technologies: report of the ISPOR rare disease special interest group","volume":"21","author":"Nestler-Parr","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.cct.2023.107198_bb0010","series-title":"Advancing Rare Disease Treatments in the COVID-19 Era and Beyond Challenges and Opportunities","first-page":"4","author":"Bevan","year":"2021"},{"key":"10.1016\/j.cct.2023.107198_bb0015","series-title":"Orphan Drug Act. P.L.","volume":"97\u2013414","year":"1983"},{"issue":"5","key":"10.1016\/j.cct.2023.107198_bb0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10928-019-09645-4","article-title":"FDA\u2019s Office of Orphan Products Development: providing incentives to promote the development of products for rare diseases","volume":"46","author":"Patel","year":"2019","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"2","key":"10.1016\/j.cct.2023.107198_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1517\/21678707.2013.749181","article-title":"Funding grants for rare diseases at the food and drug administration","volume":"1","author":"Patel","year":"2013","journal-title":"Exp. Opin. Orphan Drugs"},{"issue":"1","key":"10.1016\/j.cct.2023.107198_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-020-01514-5","article-title":"FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development","volume":"15","author":"Miller","year":"2020","journal-title":"Orphan. J. Rare Diseases."},{"key":"10.1016\/j.cct.2023.107198_bb0035","author":"US Food and Drug Administration"},{"key":"10.1016\/j.cct.2023.107198_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.640282","article-title":"Research and management of rare diseases in the COVID-19 pandemic era: challenges and countermeasures","volume":"9","author":"Chowdhury","year":"2021","journal-title":"Front. Public Health"},{"key":"10.1016\/j.cct.2023.107198_bb0045","doi-asserted-by":"crossref","DOI":"10.1177\/26330040221082673","article-title":"Impact of the Covid-19 epidemic on a US sample of patients with myasthenia gravis","volume":"3","author":"Gutierrez","year":"2022","journal-title":"Therap. Adv. Rare Disease."},{"issue":"1","key":"10.1016\/j.cct.2023.107198_bb0050","first-page":"4","article-title":"COVID-19 and rare diseases: reflections and recommendations by the international rare diseases research consortium","volume":"1","author":"Wang","year":"2021","journal-title":"Rare Disease Orphan Drugs J."},{"key":"10.1016\/j.cct.2023.107198_bb0055","author":"National Institutes of Health"},{"key":"10.1016\/j.cct.2023.107198_bb0060","author":"Bureau UC"},{"key":"10.1016\/j.cct.2023.107198_bb0065","series-title":"Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. Draft Guidance","author":"US Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.cct.2023.107198_bb0070","series-title":"FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency. Guidance","author":"US Food and Drug Administration","year":"2021"},{"key":"10.1016\/j.cct.2023.107198_bb0075","series-title":"Enhancing the Diversity of Clinical Trial Populations \u2014 Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. Guidance","author":"US Food and Drug Administration","year":"2020"},{"issue":"1","key":"10.1016\/j.cct.2023.107198_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-014-0170-0","article-title":"A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov","volume":"9","author":"Bell","year":"2014","journal-title":"Orphan. J. Rare Diseases."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714423001210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714423001210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:59:00Z","timestamp":1761555540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714423001210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":16,"alternative-id":["S1551714423001210"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2023.107198","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of the COVID-19 pandemic on US Food and Drug Administration-funded clinical trials and natural history studies for rare diseases","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2023.107198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107198"}}